Ticker

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $4.53 and traded as high as $5.4501. Galmed Pharmaceuticals shares last traded at $4.77, with a volume of 225,638 shares changing hands. Analyst Upgrades and

The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of colon tissue quality.

Xtandi® (enzalutamide) is indicated as monotherapy for the treatment of patients with non-metastatic prostate cancer (nmCSPC) at high risk of metastasis and for the treatment of patients with metastatic prostate cancer (mCSPC) who are maintaining treatment with a GnRH analogue. Global sales for Xtandi® (marketed by Astellas Pharma and Pfizer) reached approximately $8 billion and $6 billion globally in 2024 and 2025,…

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD - Get Free Report) shares passed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.62 and traded as low as $0.5753. Galmed Pharmaceuticals shares last traded at $0.5850, with a volume of 70,973 shares changing hands. Analyst Ratings Changes Separately, Weiss

Aramchol meglumine is the only SCD1 inhibitor with an established clinical safety profile and confirmed blood-brain barrier (BBB) penetration. In order to improve patient convenience and long-term treatment adherence by Parkinson patients affected by dysphagia, an ODF formulation was developed demonstrating ~150% higher systemic bioavailability and ~300% significant increase in CNS exposure than conventional oral…